

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Japara Healthcare Limited
ABN	54 168 631 052

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andrew Sudholz
Date of last notice	11 April 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	14 November 2016
No. of securities held prior to change	15,700,001 fully paid ordinary shares – indirect interest (15,127,179 held by Ashens Properties Pty Ltd as trustee for the Sudholz Family & 572,822 held by MA & JM Sudholz as trustees for the Sudholz Family Superannuation Fund) 365,779 performance rights – direct interest
Class	Performance rights
Number acquired	392,784 granted
Number disposed	-

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	15,700,001 fully paid ordinary shares – indirect interest (15,127,179 held by Ashens Properties Pty Ltd as trustee for the Sudholz Family & 572,822 held by MA & JM Sudholz as trustees for the Sudholz Family Superannuation Fund) 758,563 performance rights – direct interest
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of performance rights under the Japara Healthcare Limited Equity Incentive Plan for 2016/17 LTI arrangements, as approved by shareholders at the 2016 AGM.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Dated: 16 November 2016

⁺ See chapter 19 for defined terms.